Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022

Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Wet Age-Related Macular Degeneration (Wet-AMD) Understanding

Wet Age-Related Macular Degeneration (Wet-AMD): Overview

Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type. The wet/neovascular type affects approximately 10–15% of individuals with age-related macular degeneration but accounts for approximately 90% of all cases of severe vision loss from the disease. It causes 90% of severe vision loss in people with AMD. Everyone who gets wet AMD had dry AMD at one point. Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision. The most common symptoms typical of the onset of exudative AMD are central visual blurring and distortion. Most patients complain that straight lines appear crooked or wavy. Although only 15% of patients with AMD have the wet form, 80–90% of the severe vision loss caused by AMD results from wet AMD. Dilated funduscopic findings are diagnostic; color photographs, fluorescein angiography, and optical coherence tomography assist in confirming the diagnosis and in directing Wet AMD treatment.

""Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape is provided which includes the disease overview and Wet Age-Related Macular Degeneration (Wet-AMD) treatment guidelines. The assessment part of the report embraces, in depth Wet Age-Related Macular Degeneration (Wet-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Wet Age-Related Macular Degeneration (Wet-AMD).
• In the coming years, the Wet Age-Related Macular Degeneration (Wet-AMD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Wet Age-Related Macular Degeneration (Wet-AMD) treatment market. Several potential therapies for Wet Age-Related Macular Degeneration (Wet-AMD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Wet Age-Related Macular Degeneration (Wet-AMD) market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters

This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs

• LY09004: Luye Pharma

LY09004, a biosimilar for Eylea, is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, indicated for neovascular wAMD, macular edema following RVO, DME and diabetic retinopathy (DR) in patients with DME, and visual impairment due to pathological myopia secondary to choroidal neovascularization (PM-CNV). It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Luye Pharma.

• KSI-301: Kodiak Sciences

KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their wet AMD with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Kodiak Sciences.

• GEM-103: Gemini Therapeutics

GEM103 is a full-length recombinant complement factor H (rCFH) protein, is believed to be the first ever recombinant native complement regulator. GEM103 delivered by intravitreal injection is designed to address both complement hyperactivity and restore retinal health in patients with AMD. It is currently in the Phase II stage of development for the treatment of wAMD and is being developed by Gemini Therapeutics.

• Zimura: Iveric Bio

Zimura (avacincaptad pegol) is designed to inhibit complement factor C5 cleavage into C5a and C5b. By inhibiting the formation of complement C5 terminal fragments, Zimura may decrease the activation of inflammasomes and the formation of membrane attack complex (MAC). The drug is in Phase III clinical studies for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) and in Phase II clinical studies for wet AMD, Stargardt disease, and polypoidal choroidal vasculopathy (PCV).

• RC 28 E: RemeGen

RC 28 E is a chimeric decoy receptor trap-fusion protein that acts by dual blockade of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2. As compared to single-target EGF inhibitors, RC 28 has the potential to more effectively inhibit the abnormal blood vessel growth implicated in various diseases through both VEGF and FGF pathways, potentially allowing for a better dosing profile.

• BI 836880: Boehringer Ingelheim

BI 836880 is a humanized bispecific nanobody comprising blocking domains for VEGF and angiopoietin-2 (Ang2). BI 836880 is a potent and selective inhibitor of VEGF and Ang2. By binding to VEGF and Ang2, BI 836880 inhibits tumor angiogenesis and vascularization and enhances the tumor microenvironment to support T-cell trafficking and function in the tumor. BI 836880 is currently being investigated in Phase II clinical studies for solid tumors and in Phase I clinical studies to treat wet AMD and non-small cell lung cancer.

• AAVCAGsCD59: Janssen Research and Development

AAVCAGsCD59 is gene therapy. This drug is currently being evaluated in FDA approved clinical trials to treat both dry and wAMD. HMR59 injected in the eye increases the ability of retina cells to make a soluble form of CD59 called sCD59. The soluble CD59 circulates within the retina to block complement from further damaging the retina. AAVCAGsCD59 is currently in the Phase I stage of development for the treatment of wAMD and is being developed by Janssen Research and Development.

Further product details are provided in the report……..

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment

This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Wet Age-Related Macular Degeneration (Wet-AMD)

There are approx. 70+ key companies which are developing the therapies for Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. phase III include, Luye Pharma.

• Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights

• Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Opthea Limited
• Outlook Therapeutics
• Kodiak Sciences
• Regenxbio
• Dobecure
• Gemini Therapeutics
• Huabo Biopharm
• Isarna Therapeutics
• IVERIC bio (formerly Ophthotech Corporation)
• Tasly Pharmaceutical Group
• Ribomic
• Innovent Biologics
• GrayBug Vision
• Curacle
• Quark Pharmaceuticals
• Bio-Thera Solutions
• AngioLab Inc
• Alkahest
• Tyrogenex
• Iconic Therapeutics
• AiViva BioPharma
• Boehringer Ingelheim
• RemeGen
• PanOptica
• Clearside Biomedical
• Feramda
• AsclepiX Therapeutics
• Unity Biotechnology
• Kyowa Kirin
• Ocular Therapeutix
• Janssen Research & Development
• EyePoint Pharmaceuticals
• Shanghai Biomabs Pharmaceutical
• Aerie Pharmaceuticals
• Ashvattha Therapeutics
• Roche
• Roche
• Noveome
• Sunshine Guojian Pharmaceutical (Shanghai)
• Adverum Biotechnologies
• Zhaoke Ophthalmology
• 4D Molecular Therapeutics
• Abpro Corporation
• Novelty Nobility
• Kala Pharmaceuticals
• Kala Pharmaceuticals
• Surrozen
• Samjin Pharm

Key Products

• OPT-302
• ONS-5010
• KSI-301
• RGX-314
• Etamsylate
• GEM-103
• HB002.1M
• ISTH0036
• Zimura
• Sanhuangjingshimingwan
• RBM-007
• IBI302
• GB-102
• CU03
• PF-04523655
• BAT5906
• ALS-L1023
• AKST4290
• Vorolanib (X-82)
• ICON-1
• AIV007
• BI 836880
• RC 28 E
• PAN 90806
• CLS-AX
• AS101
• AXT107
• UBX1325
• KHK4951
• OTX-TKI
• AAVCAGsCD59
• EYP-1901
• CMAB818
• AR-13503
• D-4517
• RG6120
• RG7921
• ST266
• 601A
• ADVM-022
• TAB014
• 4D-150
• ABP-201
• NN2101
• Research Programme: Tyrosine Kinase Inhibitor
• Research Programme: Selective Glucocorticoid Receptor Modulator (SEGRM)
• Research Programs: wAMD
• SJP1803/1804